0001563577-26-000005
SEC filingGalera Therapeutics, Inc. (GRTX) reported net income of $149.0 million for FY 2025, compared to a net loss of $19.0 million in FY 2024, marking a dramatic turnaround. The primary drivers were a $151.0 million gain on extinguishment of debt and a $3.5 million gain on sale of dismutase mimetics assets to Biossil, Inc., following the asset purchase agreement in October 2025. Operating loss narrowed to $2.5 million from $20.2 million, with research and development expenses at $0.3 million (down from $3.2 million) and general and administrative at $5.7 million (down from $11.0 million). Net income attributable to common stockholders was $63.5 million, or $0.64 per share (basic and diluted), versus a $18.7 million loss or $(0.34) per share in 2024. Cash used in operating activities improved to $6.0 million from $12.1 million, with net decrease in cash of $1.9 million, ending at $6.4 million. Total assets stood at $7.2 million, liabilities at $0.6 million, and stockholders' equity at $4.0 million. The company sold its SOD mimetics portfolio and now focuses on a pan-NOS inhibitor from the Nova acquisition. Existing cash is expected to fund limited operations for at least 12 months, but additional financing is required for development amid strategic alternatives including potential dissolution.
Galera Therapeutics achieved net income of $149.0 million in FY 2025, versus a $18.957 million net loss in FY 2024. Key factors included $151.0 million gain on extinguishment of debt and $3.5 million gain on sale of dismutase mimetics assets, offsetting a $2.542 million operating loss. Loss from operations improved from $20.160 million in 2024, driven by lower R&D ($349K vs. $3.151M) and G&A ($5.693M vs. $11.002M). Net income to common stockholders was $63.524 million or $0.64 per share (98.503M weighted shares), compared to a $18.733 million loss or $(0.34) per share (54.633M shares). Balance sheet showed total assets $7.196M, down from $10.101M.
No revenue reported. As a clinical-stage biopharmaceutical company, Galera has no product sales. Gains from asset sale ($3.5M) and debt extinguishment ($151.0M) were classified in other income. Prior year included gain on litigation settlement ($0.975M) and IPR&D expense ($3.843M). Focus shifted post-sale of dismutase mimetics assets; current portfolio is pan-NOS inhibitor from Nova acquisition.
No gross margin due to absence of revenue. Operating loss margin not applicable. Profitability boosted by non-operating gains: interest income $248K, offset by warrant fair value change -$294K. Share-based compensation $410K (down from $2.545M). Single reportable segment with R&D personnel $1K, program $66K; G&A personnel $1.197M, professional fees $2.876M.
Cash used in operations $6.049M (vs. $12.145M prior), adjusted for non-cash gains on debt extinguishment ($151.0M) and asset sale ($3.5M). Investing provided $3.5M from asset sale. Financing $635K from private placement. Net cash decrease $1.914M; ending cash $6.375M (from $8.289M). Assets: cash $6.375M, prepaid $720K, total $7.196M. Liabilities $645K (accounts payable $265K, accrued $380K). Royalty liability and warrant liability extinguished to $0. Stockholders' equity $3.974M, accumulated deficit -$307.314M.
Cash and equivalents of $6.4M expected to fund limited operating expenses for at least 12 months from issuance date. Insufficient for full product development; requires additional equity/debt financing or strategic transactions. Pursuing pan-NOS inhibitor in Phase 1/2 trial funded by NIH grant. Strategic alternatives may include transaction, dissolution, or limited operations. Liquidity risks noted amid accumulated deficit $307.3M.